Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Oficina francesa de transferencia de tecnología ofrece un nuevo compuesto para el tratamiento de la diabetes

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20180410001
Publicado:
19/04/2018
Caducidad:
20/04/2019
Resumen:
Una oficina francesa de transferencia de tecnología ofrece un nuevo compuesto para el tratamiento de la intolerancia a la glucosa y, específicamente, para tratar la diabetes gracias a la administración de una conocida molécula a una dosis inferior. Investigadores de una universidad francesa han observado que el p-cresol, conocida molécula tóxica a alta concentración, es capaz de mejorar la proliferación de células secretoras de insulina en ratones a 0,5 mg/kg sin efecto tóxico. Esta nueva tecnología se dirige al mercado de medicamentos que tratan trastornos del metabolismo. La oficina de transferencia de tecnología busca compañías farmacéuticas o biotecnológicas con el fin de establecer acuerdos de licencia o cooperación técnica.

Details

Tittle:
A French Technology Transfer Office offers a new compound for the treatment of diabetes
Summary:
A French Technology Transfer Office (TTO) offers a new compound for the treatment of glucose intolerance and more precisely for the treatment of the diabetes thanks to the administration of a known molecule at a lower dosage. This new technology targets the market of drugs dealing with metabolic disorders.
The French TTO is looking for interested pharmaceutical corporations or biotechnology SMEs for a licensing agreement or for a technical cooperation agreement.
Description:
A French Technology Transfer Office (TTO) acting on behalf major life science research labs in Paris Region, has developed a new compound for glucose intolerance.
Conditions related to glucose intolerance are all characterized by impaired insulin and glucose metabolism. These kinds of intolerance cause serious damage such as liver fibrosis and abnormal fat liver content.

Diabetes represents high levels of blood sugar over a long period. Therapies available for advanced stages of diabetes mainly consist in insulin injection which presents important adverse effects such as weight gain or insulin resistance.
Accordingly, there is still a need for safer and more effective treatments for metabolic disorders.

Researchers from the French university have observed that p-cresol, known as a toxic molecule at high concentration, is able to enhance insulin secretion cells proliferation in mice at 0.5mg/kg without toxic effect.
Indeed, the administration of non-toxic doses of this compound in preclinical models of diabetes is associated with reduced body weight and adiposity, improved glucose tolerance and enhanced glucose-stimulated insulin secretion in vivo.

The partner sought could be a company interested in:
- a technical cooperation agreement to analyse the preclinical results of this new compound and launch clinical trials,
- a license agreement in order to commercialize the technology.
The TTO is ready to negotiate directly the patent rights transactions for specific applications.
Advantages and Innovations:
Compared to existing treatments such as insulin injection which induces adverse effects, the proposed new compound shows the following advantages:
- reduction of adiposity and body weight (10 to 15% less weight)
- reduction of glucose in blood (15 to 20%)
- reduction of liver fibrosis
- improvement of glucose tolerance
- increase of glucose-stimulated insulin secretion
- increase of pancreatic islet density
- no toxicity at therapeutic doses in vivo

This new treatment is significant because no adverse clinical signs were observed.

Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent application filed in 2017 in Europe, USA, Canada, China, India and Brazil

Partner sought

Type and Role of Partner Sought:
The partner sought could be a large corporate, medium-sized company or start-up operating in pharmaceutical, drug design or biotechnology development.
More precisely, the TTO targets companies involved in the field of metabolic disorders interested in developing some more efficient therapeutic solutions for diabetes and obesity.

A licensing agreement is open to pharmaceutical or biotech companies in case of further needed development to meet industrial and clinical challenges to commercialize drugs.

A technical cooperation agreement is open to manufacturing drugs firms which are able to drive pre-clinical and clinical testing of the new compound.


Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06002009 Diseño molecular
06001012 Investigaciones médicas
06002008 Microbiología
06001015 Productos farmacéuticos / medicamentos